Latest Breaking News On - Ivs 3001 - Page 1 : comparemela.com

The FDA has granted fast track designation IVS-3001 for use as a potential therapeutic option in patients with renal cell carcinoma.

United statesSamer srourJake kushnerMaung naingInvectys incUniversity of texas md anderson cancer centerCancer centerInvestigational cancer therapeuticsStem cell transplantationCellular therapyIvs 3001Patients with renal cell carcinomaThe university of texas md anderson cancer center